ClinicalTrials.gg
RecruitingNCT06999707Photon-STRIDEUpdated Oct 1, 2026

Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC

A Phase 2 interventional study of Photon radiotherapy and Tremelimumab in HCC - Hepatocellular Carcinoma, Tremelimumab and Durvalumab, sponsored by Chang Gung Memorial Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Chang Gung Memorial Hospital · Phase 2, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Oct 1, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies testing tremelimumab in Carcinoma, Hepatocellular — 15 open to participants now, 28 under way, 5 of them phase 3. tremelimumab · Carcinoma, Hepatocellular.

Planned enrollment
14th of 34
45 · median 35
Started
2025
with 6 others
Phase 2
24 of 34
11 open now
Primary completion
2030-05
later than 26 of 27 live
Registered
29th of 34
by date
Lead sponsor
2 of 34
Chang Gung Memorial Hospital

Among the 34 studies testing tremelimumab in Carcinoma, Hepatocellular, this one is the 14th largest by planned enrollment, is one of 7 that started in 2025, is one of 24 in phase 2, reaches primary completion later than 26 of the 27 other live ones, and was the 29th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

15 of the 34 studies testing tremelimumab in Carcinoma, Hepatocellular are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About tremelimumab

tremelimumab: first FDA approval 2022 (IMJUDO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing tremelimumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

Tremelimumab plus durvalumab (the STRIDE regimen) is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC); however, it demonstrates limited efficacy, with an objective response rate (ORR) of only 20.1%. Radiation therapy (RT) is highly effective in controlling localized solid tumors and has become an integral component of the treatment algorithm for unresectable HCC. Preclinical studies have shown that combining RT with PD-L1/PD-1 blockade promotes immunogenic cell death and enhances antigen presentation by dendritic cells, thereby boosting systemic T cell-mediated antitumor responses in mouse models. The addition of CTLA-4 inhibition further enhances antigen cross-priming following RT. Recent retrospective data also indicate that combining RT with immune-oncology agents is associated with improved overall survival and prolonged time to progression compared to RT or immunotherapy alone. However, the clinical benefit and immunologic impact of combining RT with tremelimumab and durvalumab have not yet been evaluated in prospective clinical trials for unresectable HCC.

This phase II, single-arm clinical trial aims to assess the safety, efficacy, and immunologic effects of combining proton RT with tremelimumab and durvalumab in patients with unresectable HCC.

03

Conditions studied

  • HCC - Hepatocellular Carcinoma
  • Tremelimumab
  • Durvalumab
  • Radiotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must have diagnosis of HCC that is deemed unsuitable for surgical resection or transplant. Participants may have multiple lesions with a total maximal tumor dimension of \< 20 cm, and no one lesion > 15 cm. Diagnosis should be confirmed by at least 1 criterion listed below:

    • or cytologically proven diagnosis of HCC.
    • Typical arterial enhancement and delayed washout on multiphasic CT or MRI.
  2. Age ≥18 years at the time of signing document.
  3. performance status 0-1.
  4. Barcelona Clinic Liver Cancer (BCLC) stages Intermediate (B) or Advanced (C).
  5. score 5-6 liver function within 28 days of study registration.
  6. Documented virology status of virus (HBV), as confirmed by screening HBV serology test.
  7. Documented virology status of virus (HCV), as confirmed by screening HCV serology test.
  8. Ability to understand and the willingness to sign a written informed consent document
  9. Adequate bone marrow, liver, and renal function within 4 weeks before study registration

    • ≥ 9.0 g/dL
    • (ANC) ≥ 1,000/mm3
    • count ≥ 50,000/μL
    • Total \< 2.5 mg/dL
    • Serum albumin >2.8 g/dL
    • (ALT) and aspartate aminotransferase (AST) ≤ 3 × (ULN)
    • ≤ 6 seconds prolonged
    • Serum creatinine ≤ 1.5 mg/dL

Exclusion criteria

Exclusion Criteria:

  1. Prior invasive unless disease free for a minimum of 2 years
  2. Prior radiotherapy to the region of the liver that would result in overlap of radiation therapy fields
  3. Prior selective internal radiotherapy/hepatic arterial yttrium therapy, at any time
  4. Untreated active or
  5. Moderate to severe or intractable ascites
  6. Presence of distant that cannot be encompassed by photon radiotherapy
  7. Untreated or incomplete treated esophageal or gastric varices
  8. Severe, active co-morbidity, defined as follows:

    • Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration
    • Myocardial infarction within the last 6 months prior to study entry
    • Acute bacterial or fungal infection requiring intravenous antibiotics within 28 days prior to study entry
    • A bleeding episode within 6 months prior to study entry due to any cause.
    • Thrombolytic therapy within 28 days prior to study entry.
    • Known bleeding or clotting disorder.
    • Uncontrolled psychotic disorder
  9. Pregnancy or women of and men who are sexually active and not willing/able to use medically acceptable forms of
  10. Prior solid organ transplantation.
  11. Prior or active disease (AID) including autoimmune hepatitis, inflammatory bowel disease, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren's syndrome, Guillain-Barre syndrome, and multiple sclerosis.
  12. Inability to treat all sites of disease by photon radiotherapy (such as extrahepatic metastases or massive liver tumors whereby the liver constraints cannot be met for covering all sites of liver tumors using photon radiotherapy.)
  13. Known infection.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Photon radiotherapy combined with Tremelimumab and Durvalumab

    Patients undergo photon radiotherapy combined with Tremelimumab and Durvalumab.

    Radiation: Photon radiotherapy · Drug: Tremelimumab · Drug: Durvalumab

Interventions

  • RadiationPhoton radiotherapy

    * 39.6-72.6 Gy in 22 fractions for tumors ≤1 cm from hepatic hilum, bowel, and heart. * 30-66 Gy in 10 fractions for tumors \>1 cm from hepatic hilum, bowel, and heart. * 27.5-50 Gy in 5 fractions using stereotactic body radiation therapy (SBRT) techniques

  • Tremelimumab 300 mg will be administered as an IV infusion for one dose

  • Treatment Duration Guidelines: \* Complete Response (CR): Patients who achieve a CR within one year of treatment will continue durvalumab for a total duration of two years. \* Partial Response (PR): Patients who achieve a PR should continue durvalumab until achieving CR, disease progression (PD), or for a total duration of two years. \* Stable Disease (SD): Patients with SD will receive duvalumab for a total of 6 doses.

06

What researchers measure

Primary outcomes

  1. Progression free survival

    Progression free survival is defined as the time from signing the informed consent to the first occurrence of disease progression or death from any cause (whichever occurs first) according to RECIST1.1

    Time frame: 12 months

Secondary outcomes

  1. Local control

    Local control is defined as the time from signing the informed consent to the first occurrence of disease progression in the irradiated field according to RECIST1.1

    Time frame: 12 months

  2. Time to progression

    Time to progression is defined as the time from signing the informed consent to the first occurrence of disease progression according to RECIST1.1

    Time frame: 12 months

  3. Overall Response Rate

    Overall Response Rate is defined as a complete or partial response according to RECIST1.1

    Time frame: 12 months

  4. Overall survival

    Overall survival is defined as the time from signing the informed consent to death from any cause.

    Time frame: 12 months

  5. Incidence and severity of adverse events

    Description: Adverse events will be graded using CTCAE v5

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Chang Gung Memorial Hospital at Linkou
    Taoyuan City, Taiwan 333, Taiwan
    Recruiting
    • Rodney Cheng-En Hsieh, MD, PhD · Contactrodney445@gmail.com · +886-3-328-1200
    • Rodney Cheng En Hsieh, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — Sharing individual participant data (IPD) with other researchers requires IRB review and approval. Presently, we do not have a plan to provide IPD to other researchers.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2030, 60 months after the start.

Of 352 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's planned 60 months is above that.

Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2025
First posted
May 31, 2025
StartActual
May 22, 2025
Primary completionEst.
May 31, 2030
CompletionEst.
May 31, 2033
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Chang Gung Memorial Hospital at Linkou · Taoyuan City, Taiwan
Show 1 removed
  • Chang Gung Memorial Hospital at Linkou · Taoyuan City, Taiwan
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    1 site added, 1 site removed
    Show site
    • Chang Gung Memorial Hospital at Linkou · Taoyuan City, Taiwan
    Show 1 removed
    • Chang Gung Memorial Hospital at Linkou · Taoyuan City, Taiwan
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06999707
Responsible party
Sponsor
First posted
May 31, 2025
Start date
May 22, 2025
Primary completion
May 31, 2030 (estimated)
Completion
May 31, 2033 (estimated)
Last update
Oct 1, 2026

Study contacts

Rodney Cheng-En Hsieh, MD, PhD
Contact
rodney445@gmail.com
+886975361338 ext. 7000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tremelimumab · Durvalumab

Start the discussion